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Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syn-
drome, is a complex multifactorial disease characterized by metabolic deregulations that
include accumulation of lipids in the liver, lipotoxicity, and insulin resistance. The progres-
sion of NAFLD to non-alcoholic steatohepatitis and cirrhosis, and ultimately to carcinomas,
is governed by interplay of pro-inflammatory pathways, oxidative stress, as well as fibro-
genic and apoptotic cues. As the liver is the major organ of biotransformation, deregulations
in hepatic signaling pathways have effects on both, xenobiotic and endobiotic metabolism.
Several major nuclear receptors involved in the transcription and regulation of phase I
and II drug metabolizing enzymes and transporters also have endobiotic ligands including
several lipids. Hence, hepatic lipid accumulation in steatosis and NAFLD, which leads to
deregulated activation patterns of nuclear receptors, may result in altered drug metabo-
lism capacity in NAFLD patients. On the other hand, genetic and association studies have
indicated that a malfunction in drug metabolism can affect the prevalence and severity of
NAFLD. This review focuses on the complex interplay between NAFLD pathogenesis and
drug metabolism. A better understanding of these relationships is a prerequisite for devel-
oping improved drug dosing algorithms for the pharmacotherapy of patients with different
stages of NAFLD.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most common
chronic liver disease in Western countries with a wide disease spec-
trum. It ranges from the hepatic accumulation of lipids known as
steatosis, non-alcoholic steatohepatitis (NASH) wherein steatosis
is accompanied by inflammation and can further progress to cir-
rhosis and hepatocellular carcinoma. NAFLD is the hepatic man-
ifestation of the metabolic syndrome as it is frequently associated
with obesity, insulin resistance, hyperglycemia, hypertension, and
dyslipidemia (Anderson and Borlak, 2008; Lewis and Mohanty,
2010; Cohen et al., 2011).
The accumulation of hepatic triglycerides due to an imbalance
between free fatty acids uptake, de novo lipogenesis, oxidation,
esterification, and secretion, is a hallmark of hepatic steatosis
(Donnelly et al., 2005). Initially the progression of NAFLD to
NASH was described as a two-hit event, with the accumulation
of hepatic triglycerides being the first hit, which in turn triggers
the second hit – inflammation and oxidative stress (Crespo et al.,
2001; Browning and Horton, 2004; Sunny et al., 2011; Wree et al.,
2011). An extended hypothesis proposed a reduced capacity of
hepatic regeneration and the detrimental effects of free fatty acid
lipotoxicity as the third hit (Feldstein et al., 2004; Day, 2006).
Several other factors contribute to the induction of NAFLD
and/or to its progression. These include compromised adipose
tissue storage and function (Calvert et al., 2007), upregulation of
inflammatory factors, and reactive oxygen species (ROS; Crespo
et al., 2001; Browning and Horton, 2004; Wree et al., 2011), the
interaction of the intestinal microbial populations with the host
through the inflammasome (Henao-Mejia et al., 2012), downreg-
ulation of the endoplasmic reticulum stress and protein ubiquiti-
nation pathways (HSPA5, USP25), and gene expression changes in
cell development, morphology, movement, death, and antigen pre-
sentation pathways (Gawrieh et al., 2010). Insulin resistance also
plays a detrimental role in the pathogenesis of NAFLD. Polymor-
phisms that may potentially explain this effect were identified in
the insulin receptor-substrate 1 (IRS-1; Gly172Arg; Dongiovanni
et al., 2010).
As a multifactorial disorder, NAFLD is characterized by inter-
actions between genetic and environmental factors, thus proving
it difficult to understand its manifestations (Fon Tacer and Roz-
man, 2011; Lorbek and Rozman, 2012). Moreover, the scarcity of
robust non-invasive diagnostic methods represents an obstacle in
accurately determining the prevalence of NAFLD (Ratziu et al.,
2011). By current estimations, NAFLD has a prevalence rate of
6–35% with a median of 20%, depending on the population stud-
ied and the method of assessment (Vernon et al., 2011; Chalasani
et al., 2012). Ethnic differences in the prevalence of NAFLD also
exist, with a lower frequency in African–Americans compared to
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Hispanic-Americans (Wagenknecht et al., 2009; Stepanova et al.,
2010). It occurs in children (Roberts, 2007) and adults of all age
groups, however conflicting observations have been made regard-
ing the gender-specific risk of NAFLD (Bedogni et al., 2005; Chen
et al., 2008b). The prevalence of NASH is much lower, affect-
ing 2–5% of the population (Neuschwander-Tetri and Caldwell,
2003; Vernon et al., 2011), however, its frequency escalates with
increasing age, body mass index (BMI), more severe forms of
insulin resistance, hypertriglyceridemia, and poor liver function.
Increased progression to NASH is observed in Hispanics, possibly
due to the large-scale adaptation of western lifestyles (Brown-
ing et al., 2004). Obese individuals (BMI> 30 kg/m2) are at a
higher risk of developing NAFLD, with a prevalence of 85–98%
for NAFLD and >25% for NASH (Machado et al., 2006). Fur-
thermore, diabetes mellitus (Type 2 Diabetes, T2D) is a major
determinant of NAFLD with a 70% prevalence of NAFLD in some
diabetic populations (Targher et al., 2006; Leite et al., 2009). How-
ever, NAFLD also occurs in approximately 18% of normal weight
non-diabetic populations (de Alwis and Day, 2008).
Due to the lack of targeted drugs, NAFLD patients are usu-
ally treated by cholesterol-lowering statins, fibrates, or anti-
diabetics such as thiozolidinediones, sulfonylureas, etc. (Rozman
and Monostory, 2010). The controversy regarding the NAFLD
patients’ benefits versus the potential harm due to liver toxicity
is however, a matter of investigations and vivid debates.
NAFLD AND DRUG DISPOSITION
Liver is the major organ of endogenous and xenobiotic metabo-
lism. In healthy livers, the metabolic processes are in homeostasis.
A long-term disturbance of one or more metabolic pathways can
provoke liver diseases. The intracellular accumulation of xeno-
and endo-biotics is potentially toxic and is regulated at several
levels including uptake, biotransformation, and elimination by
drug metabolizing enzymes (DMEs). DMEs are classified as phase
I, mainly cytochrome P450s (CYPs) that catalyze hydroxylation
reactions, or phase II enzymes that are involved in conjugation
reactions. Human phase I DME subfamilies CYP3A and CYP2C
account for 50% of all hepatic CYPs and metabolize a large num-
ber of diverse drugs, e.g., lovastatin, tamoxifen, and R-warfarin.
Phase II DMEs include UDP-glucuronosyltransferases (UGTs),
sulfotransferases (SULTs), N -acetyltransferases, and several other
transferases that transform compounds into more excretable
forms. Transporters such as organic anion transporting polypep-
tide (OATP) and ATP-binding cassette (ABC)-transporters are
responsible for the hepatocellular uptake and excretion of xeno-
biotics. The expression of phase I and II DMEs and transporters
is regulated by a battery of nuclear receptors in a coordinated
manner (Aleksunes and Klaassen, 2012).
Non-alcoholic fatty liver disease patients show differences in
drug metabolism and its regulatory components, as summarized
in Tables 1–3. Compared to normal subjects, a pediatric NAFLD
population exhibited altered glucuronidation of acetaminophen,
a commonly used analgesic and antipyretic agent known to cause
acute hepatic failure (Barshop et al., 2011). Although the phar-
macokinetic profile of acetaminophen in both the normal and
NAFLD subjects was unaltered, this study highlighted changes
in the biotransformation of the drug and the possibility of
compensation by other excretory pathways in the presence of
NAFLD. Similarly, the metabolism of ezetimibe, an intestinal
cholesterol-uptake blocker, is altered in NASH patients due to dif-
ferential localization of ABCC2 and ABCB1 efflux transporters,
hence, resulting in plasma retention of the active glucuronide
metabolite of ezetimibe (Hardwick et al., 2012b). Studies have also
indicated a reduced efficacy of certain treatments in NAFLD con-
dition, such as the novel oral hypoglycemic sitagliptin, a dipeptidyl
peptidase-4 (DPP-4) inhibitor. T2D patients with NAFLD have
increased serum DPP-4 activity, an enzyme that inhibits incretins
such as glucagon-like peptide 1 (GLP-1), and thus, reduced efficacy
of sitagliptin (Firneisz et al., 2010; Iwasaki et al., 2012).
Several drug metabolizing CYPs are downregulated in genet-
ically modified (e.g., leptin deficient ob/ob, dysfunctional lep-
tin receptor db/db mice) and diet-induced [e.g., high-fat diet,
methionine- and choline-deficient (MCD) diet] NAFLD animal
models and in patients with characteristics of the metabolic syn-
drome (Buechler and Weiss, 2011; Ghose et al., 2011). Genome
wide association and candidate gene studies have identified single
nucleotide polymorphisms (SNPs) in DMEs that associate with
NAFLD prevalence, progression, or severity, highlighting the role
of altered drug metabolism in NAFLD pathogenesis (Anstee et al.,
2011; Lake et al., 2011). Thus, there is ample evidence for altered
xenobiotic metabolism and efficacy in NAFLD patients.
A function of CYPs in hepatic lipid homeostasis is indicated
by their broad role in microsomal oxidation, cholesterol biosyn-
thesis, and their activation by lipids. Further proof of this role
was observed from studies in the liver conditional CYPs reduc-
tase microsomal flavoprotein NADPH: CYP oxidoreductase (Por)
null mice. POR is an essential redox partner of the micro-
somal CYPs. The liver conditional Por knockout mice display
hepatomegaly, hepatic steatosis, and a reduced capacity of drug
metabolism (Gu et al., 2003). One of the CYPs, CYP51, is an
essential enzyme of cholesterol synthesis (Keber et al., 2011).
Cholesterol and its metabolites are also known to contribute to
lipotoxicity and inflammation-mediated progression of NAFLD to
NASH (Caballero et al., 2009). The cholesterol synthesis pathway
responds to feedback regulation by cholesterol, TNF-α stimula-
tion (Tacer et al., 2007), and xenobiotics, such as statins (Rezen
et al., 2008, 2009; Rozman and Monostory, 2010), thus empha-
sizing the hepatic crosstalk between endobiotic and xenobiotic
metabolism and inflammation. Endobiotics and xenobiotics acti-
vate various nuclear receptors and thus influence the expression of
genes involved in the various hepatic metabolic pathways (Gao and
Xie, 2010). The interplay between metabolism of endobiotics and
xenobiotics is a frequent cause of drug side effects that can now be
explained at the molecular level (Hafner et al., 2011; Rezen, 2011).
NUCLEAR RECEPTORS REGULATING DMEs
Pregnane X receptor
Pregnane X receptor (PXR, NR1I2) is a ligand-activated nuclear
receptor that upon activation forms a heterodimer with retinoid
X receptor (RXR) and regulates the expression of a wide range
of DMEs (Tolson and Wang, 2010). Apart from being activated
by xenobiotics, it also responds to endobiotics including bile
acids (Xie et al., 2001) and steroid hormones (di Masi et al.,
2009). In mice, PXR activation results in hepatic steatosis due to
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Table 1 | Nuclear receptors and transcription factors in interaction between NAFLD and drug metabolism.
Nuclear receptor/
transcription factor
Targets Association with NAFLD
Pregnane X receptor
(PXR)
CYP2C9
CYP3A4
CYP2B6
UGT1A1
MDRP1 P-glycoprotein
CD36
Activation in mice causes hepatic steatosis due to enhanced lipogenesis,
decreased β-oxidation, and increased uptake of fatty acids via CD36 activation
(Zhou et al., 2006b)
A NAFLD population of European descent displayed strong association between
rs2461823/A and rs7643645/G-containing haplotypes and disease severity
irrespective of BMI and HOMA index (Sookoian et al., 2010)
Constitutive androstane
receptor (CAR)
CYC2C9
CYP2B6
CYP3A4
UGT1A1
Car+/+ mice fed MCD diet develop increased liver fibrosis (Yamazaki et al., 2007)
Activation results in the induction of aberrant hepatic DNL and insulin resistance
via the expression of THRSP (Anderson et al., 2009; Rezen et al., 2009; Breuker
et al., 2010)
Lowers plasma concentration of HDL (Masson et al., 2008)
Farnesoid X receptor
(FXR)
CYP7A1
BSEP
Deficiency in a mouse model of hypercholesterolemia fed on a HFD results in
features of NASH (Kong et al., 2009)
FXR*1B (-1T) is associated with decreased FXR expression and functionality
(Marzolini et al., 2007)
Liver X receptor (LXR) SREBP-1c
PPARγ
chREBP
CD36
ABC1, ABCG1, ABCG5, ABCG8
Involved in lipid biosynthesis, cholesterol and bile acid homeostasis, and fatty acid
uptake (Handschin and Meyer, 2005; Rezen et al., 2011)
Plays a crucial function in glucose tolerance, insulin secretion, and adipocyte size
(Efanov et al., 2004; Gerin et al., 2005)
rs17373080[G] polymorphism in LXRβ associated with 20–30% lower risk of T2D
prevalence but a higher risk of obesity (Dahlman et al., 2009; Solaas et al., 2010)
Peroxisome proliferator-
activated receptor
(PPAR)
ACS Fibrates are utilized to treat patients with elevated plasma triglycerides
CPT-I
SULT 1C1, 1C2, 1E1, 2A1, 2A2, 3A1
UGT1A1, UGT1A3, UGT1A6, UGT2B4
PPARα activates fatty acid oxidation and hepatic lipid hydrolysis and
downregulates hepatic triglyceride secretion (Kersten et al., 1999; Pyper et al.,
2010; Rakhshandehroo et al., 2010)
Pparα-deficient mice develop hepatic steatosis on a high-fat diet (HFD;
Abdelmegeed et al., 2011)
Potential protective role for the Val227Ala variant of PPARα against obesity
compared to wild-type variant (Chen et al., 2008a)
Nuclear factor erythroid
2-related factor 2 (Nrf2)
GST
HO-1, Nqo1, GCLC
Mrp2/ABCC2
Null mice on MCD diet exhibit increased hepatic steatosis, inflammation, and
oxidative stress (Chowdhry et al., 2010)
Rats fed with an MCD diet display Nrf2-dependent upregulation of oxidative
stress response (Lickteig et al., 2007)
enhanced sterol regulatory element-binding protein-1c (SREBP-
1c)-independent lipogenesis, decreasedβ-oxidation,and increased
uptake of fatty acids via fatty acid translocase (FAT/CD36) activa-
tion (Zhou et al., 2006b). The activation of CD36 by PXR in mice
occurs directly or via the activation of peroxisome proliferator-
activated receptor gamma (PPARγ; Tontonoz et al., 1998; Zhou
et al., 2006b). PXR also plays a role in glucose metabolism (Gao and
Xie, 2012). It inhibits gluconeogenesis by inactivating hepatocyte
nuclear factor-4 (HNF-4) and forkhead box protein O1 (FOXO1),
both of which are positive regulators of gluconeogenic genes
(Bhalla et al., 2004; Kodama et al., 2004). Genetic association stud-
ies in a European NAFLD population indicated an association of
the PXR rs2461823[A] and rs7643645[G]-containing haplotypes
and disease severity, irrespective of BMI and homeostatic model
assessment (HOMA) index (Sookoian et al., 2010). Although PXR
activation increases steatosis, PXR-dependent counteraction of
inflammation by inhibition of nuclear factor kappa-B (NFκB) has
also been documented in human and mouse samples (Zhou et al.,
2006a). In support of the previous statement, rats treated with
a PXR activator pregnenolone-16α-carbonitrile (PCN) displayed
reduced hepatic fibrosis and necrosis in response to a fibrogenesis-
inducing agent carbon tetrachloride (CCl4; Marek et al., 2005). It
is thus plausible that PXR polymorphisms associated with NAFLD
may affect disease severity by lowering PXR activity, thus result-
ing in increased susceptibility to NASH. Another link between
PXR and NAFLD is through the modulation of DMEs. PXR
induces the expression of CYP2C9 (Gerbal-Chaloin et al., 2002),
which metabolizes the anti-diabetic drug rosiglitazone known to
reduce liver fat. Since rosiglitazone is used in NAFLD patients
with hyperglycemia and IR (Ratziu et al., 2008), patients with PXR
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Table 2 | Phase I drug metabolizing enzymes implicated in the pathogenesis of NAFLD.
Phase 1 DME Drugs metabolized/transported Association with NAFLD
CYC2C9 Roziglitazone (anti-diabetic)
Sulphanylureas (anti-diabetic)
Warfarin (anti-coagulant)
Tamoxifen (selective estrogen
receptor modulator)
Loss-of-function variants associated with increased response to sulfonylurea drugs, a NAFLD
treatment, and an increased glycemic response in the treatment of T2D patients (Zhou et al., 2010)
mRNA and enzyme activity increases with NAFLD progression (Fisher et al., 2009b)
CYP3A4 Atorvastatin (statin)
Simvastatin (statin)
Lovastatin (statin)
Fibrates (anti-dyslipidemia)
Nateglinide (anti-diabetic)
Docetaxel (anti-cancer)
Expression and activity affected by SNPs in the PXR coding, non-coding, and promoter regions, in
PPARα and POR (Zhang et al., 2008; Gomes et al., 2009; Klein et al., 2012)
Intron 6 SNP rs35599367[T] in CYP3A4 results in decreased expression and activity of CYP3A4 and
carriers of the T allele require significantly lower doses of statins to treat dyslipidemia (Elens et al.,
2011; Wang et al., 2011)
CYP3A activity shows a negative correlation with the severity of steatosis (Kolwankar et al., 2007)
Displays sexual dimorphism with elevated expression in premenopausal women with a more
favorable lipid profile, compared to men (Wolbold et al., 2003)
CYP2E1 Propranolol (beta-blocker)
Paracetamol (analgesic)
Catalyzes fatty acid oxidation in hepatic microsomal compartments and is implicated in NASH
development (Williams, 2004)
NAFLD and NASH patients and animal models display enhanced expression of CYP2E1 and lipid
peroxidation (Robertson et al., 2001), with increased localization to areas in the liver with oxidative
stress injuries, leptinemia, reduced adiponectin levels and insulin resistance in NAFLD (Weltman
et al., 1996, 1998)
Contrasting observations indicated decreased CYP2E1 mRNA and protein levels and no changes in
its activity at progressive stages of NAFLD (Aubert et al., 2011)
Cyp2e1-null mice that still displayed lipid peroxidation had increased expression of Cyp4a10 and
Cyp4a14 genes (Fisher et al., 2009b; Mitsuyoshi et al., 2009)
CYP4A Fatty acid derivatives Enhanced activity results in increased production of ROS, thus contributing to steatohepatitis
In contrast, Pparα-null mice on an MCD diet are more prone to developing NASH in the absence of
Cyp4a induction (Leclercq et al., 2000; Hardwick et al., 2009)
gene variants may theoretically suffer from aberrant rosiglitazone
metabolism. PXR is thus a potential pharmacogenetic marker for
thiazolidinedione treatments. Furthermore, PXR is a strong mod-
ulator of CYP3A4, the major phase I DME in humans. Several
SNPs that affect the expression of CYP3A4 reside within the PXR
coding, non-coding, and promoter regions (Zhang et al., 2008).
Since many NAFLD patients are treated with drugs metabolized
by CYP3A4, further pharmacogenetic evaluation of patients with
these PXR variants is required (Table 1).
Constitutive androstane receptor
Constitutive androstane receptor (CAR, NR1I3) is also a key reg-
ulator of xenobiotic and endobiotic metabolism (Moore et al.,
2000; Handschin and Meyer, 2005). Upon ligand activation, CAR
is translocated to the nucleus where it binds to DNA elements
of DME genes such as CYP2B6, CYP3A4 CYP2Cs, and others
(Sueyoshi and Negishi, 2001; Gerbal-Chaloin et al., 2002; Faucette
et al., 2006; Chen and Goldstein, 2009), as well as phase II enzymes
involved in glucuronidation (Sugatani et al., 2005), sulfation, and
drug transport (Tolson and Wang, 2010). Several studies also indi-
cate a role of CAR in energy homeostasis (Wada et al., 2009).
Hence, the activation of CAR for regulation of energy homeosta-
sis may affect drug metabolism (Hafner et al., 2011). SREBP-1c,
which is upregulated in hepatic steatosis, inhibits CAR and thus,
may further contribute to aberrant xenobiotic and endobiotic
metabolism (Roth et al., 2008). Car+/+ mice fed with MCD
diet, known to induce NASH (Rinella et al., 2008), developed
enhanced liver fibrosis due to lipid peroxidation, inducible nitric
oxide synthase (iNOS), and increased CYP induction compared
to Car−/− mice (Yamazaki et al., 2007). However, no difference
in hepatic lipid accumulation was observed between Car+/+ and
Car−/−mice, indicating that CAR may be involved in later stages
of NAFLD progression and hepatocarcinogenesis (Takizawa et al.,
2011). Furthermore, observations in Car−/− mice and human
hepatocytes highlight the role of CAR activation in the induction
of aberrant hepatic de novo lipogenesis and insulin resistance by
enhancing the expression of thyroid hormone-responsive spot 14
protein (THRSP ; Anderson et al., 2009; Breuker et al., 2010). Acti-
vation of CAR in mice with 1,4-Bis [2-(3,5-dichloropyridyloxy)]
benzene (TCPOBOP) increased serum triglycerides and hepatic
fatty acid synthesis and repressed adaptation to hyperlipidemia,
which is expected to favor the development of NAFLD (Rezen
et al., 2009). Contradictory observations arise from other mouse
models, where CAR has been linked to improved fatty liver due
to decreased lipogenesis, increased β-oxidation, improved glu-
cose tolerance, and insulin sensitivity (Dong et al., 2009; Gao
et al., 2009). In mice, CAR also regulates cholesterol and bile acid
metabolism by lowering plasma high-density lipoprotein (HDL)
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Table 3 | Phase II drug metabolizing enzymes and transporters implicated in the pathogenesis of NAFLD.
Phase II DME/transporter DRUGS metabolized/transported Association with NAFLD
Glutathione-S-transferases
(GSTs)
Chlorambucil (anti-cancer)
Busulfan (anti-cancer)
Cyclophosphamide (anti-cancer)
GSTM2, GSTM4, and GSTM5 mRNA levels decreased in patients with steatosis
and NASH (Ip et al., 2003)
Overall GST activity decreased with disease progression, accompanied by a
reduced pool of glutathione, highlighting the depleted ability to combat oxidative
stress in NAFLD patients (Younossi et al., 2005)
Lower expression in Caucasians compared to African–Americans (Hardwick et al.,
2010)
GSTM1-null genotype present at a higher frequency in NAFLD subjects
(Stepanova et al., 2010)
Sulfotransferases (SULTs) Acetaminophen (analgesic)
Albuterol (β2-adrenergic agonist)
Terbutaline (β2-adrenergic agonist)
Hormonal contraceptives
SULT2B1b has anti-lipogenic properties by suppressing the LXR-SREBP1c
interaction, resulting in decreased hepatic and serum level of lipids in Ldlr -null
mice on a HFD (Hori et al., 2007, 2009)
SULT1A2 expression is downregulated in NASH patients compared to control
obese individuals (Bai et al., 2012)
SULT1C4 and SULT4A1 have increased mRNA and protein levels in human NASH
samples compared to control and steatosis samples (Younossi et al., 2005)
UDP
glucuronosyltransferases
Non-steroidal anti-inflammatory
drugs
Opioids
Anti-depressants
Anti-psychotics
Mice with severe hepatic steatosis induced by a high-fat and high-sucrose diet,
display increased expression of Ugt1a1 and Ugt1a6 via interaction with CAR and
PXR (Hardwick et al., 2012a)
The UGT1A1*6 allele has a protective effect against NAFLD in a population of
obese Taiwanese children (Osabe et al., 2008)
ABCC2 Pravastatin (statin)
Vinblastine (anti-cancer)
Ceftriaxone (antibiotic)
Decreased in rodent models of obesity, NAFLD and NASH and normalized on
roziglitazone treatment (Lin et al., 2009)
rs17222723 and rs8187710 variants in the ABCC2 are significantly associated
with NAFLD patients and clinical and histological parameters (Geier et al., 2005;
Fisher et al., 2009a; Martin et al., 2010)
Uptake transporters (NTCP,
OATP1a1, 1a4, 1b2, 2b1,
OAT2, and OAT3)
Atorvastatin (statin) Downregulation of uptake transporters in the transition from steatosis to NASH
rather than between control and steatotic samples (Sookoian et al., 2009)Pravastatin (statin)
Rosuvastatin (statin)
Non-steroidal anti-inflammatory
drugs
Captopril (anti-hypertension)
and reverse cholesterol transport, possibly via downregulation of
apolipoprotein A1 (ApoA1; Masson et al., 2008). CAR polymor-
phisms have not yet been linked to metabolic diseases; however,
its role in glucose and lipid metabolism and its functional redun-
dancy with PXR highlights that the CAR gene is an important
candidate for NAFLD association studies (Rezen et al., 2009).
FXR and LXR
Farnesoid X receptor (FXR) and Liver X receptor (LXR) are
not major regulators of xenobiotic metabolism, but they play an
important role in the metabolism of cholesterol and bile acids
(Rezen et al., 2011). FXR/NR1H4 is the predominant regula-
tor of bile acid synthesis and secretion, thereby lowering hepatic
cholesterol levels. The first and rate-limiting step of bile acid syn-
thesis from cholesterol is catalyzed by cholesterol 7α-hydroxylase
(CYP7A1). The activation of FXR in primary human and mouse
hepatocytes results in decreased transcription of CYP7A1 due to
an indirect negative feedback mechanism (Goodwin et al., 2000;
Holt et al., 2003). Furthermore, activated FXR upregulates the
expression of CYP3A4, which hydroxylates some common bile
acids into more soluble forms (Gnerre et al., 2004), as well as the
bile salt export pump (BSEP; Ananthanarayanan et al., 2001; Plass
et al., 2002; Song et al., 2008). Deficiency of FXR in an Ldlr−/−
mouse model of hypercholesterolemia on high-fat diet results in
features of NASH, such as macrosteatosis, hepatocyte ballooning,
and inflammation (Kong et al., 2009). A common SNP, FXR∗1B
(-1T), has been identified in the sequence flanking the start codon
of FXR in European, African, Chinese, and Hispanic-American
populations. It associates with decreased FXR expression and func-
tionality, which may contribute to the pathogenesis of metabolic
disorders (Marzolini et al., 2007). However, association of this FXR
polymorphism with NAFLD in humans has not yet been identified.
Liver X receptor plays important roles in lipid biosynthesis
as well as cholesterol and bile acid homeostasis (Handschin and
Meyer, 2005; Rezen et al., 2011). Typical activators of LXR are
oxysterols such as 22(R)-hydroxycholesterol (22(R)-HC), 24(S),
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25-epoxycholesterol, and 25-hydroxycholesterol (Jakobsson et al.,
2012). LXR activation not only increases cholesterol catabo-
lism but also hepatic lipogenesis through activation of SREBP-
1c, PPARγ, or carbohydrate response element-binding protein
(chREBP; Lee et al., 2008). LXR and PXR share many target genes
(Boergesen et al., 2012) and both regulate the uptake of fatty acids
into hepatocytes via expression of FAT CD36 (Zhou et al., 2006b).
Although LXR activates Cyp7a1 expression during bile acid syn-
thesis in rodents, it does not have an effect on human CYP7A1
expression (Goodwin et al., 2003). In humans, the LXRα isoform
is mainly expressed in tissues involved in lipid metabolism, where
it regulates the expression of cholesterol transporter genes, such
as the ABC transporters ABC1 (Schwartz et al., 2000), ABCG1
(Sabol et al., 2005), ABCG5 (Repa et al., 2002), and ABCG8 (Repa
et al., 2002). LXRβ, the ubiquitously expressed isoform and the
only isoform present in pancreatic β-cells, does not play a role in
cholesterol homeostasis (Alberti et al., 2001) but has a crucial role
in glucose tolerance, insulin secretion, and adipocyte size (Efanov
et al., 2004; Gerin et al., 2005). The rs17373080[G] polymorphism
in LXRβ associates with a 20–30% lower risk of T2D but with
a higher risk of obesity, as observed in two independent studies
(Dahlman et al., 2009; Solaas et al., 2010). This is in accordance
with data on Lxrβ-null mice that display a lean phenotype with
glucose intolerance (Gerin et al., 2005). According to the best of
our knowledge, LXR polymorphisms have not yet been linked to
NAFLD.
Peroxisome proliferator-activated receptors
Peroxisome proliferator-activated receptors (PPARs) are tran-
scription factors that are activated by endogenous ligands, such
as fatty acids, and synthetic ligands, such as the hypolipidaemic
fibrates and the insulin-sensitizing thiozolidinediones. Like PXR
and CAR, they form heterodimers with RXR and transactivate
numerous target genes with vital roles in metabolism by binding
to PPAR response elements (PPRE; Nielsen et al., 2008; van der
Meer et al., 2010). The identified subtypes PPARα, PPARγ, and
PPARβ/δ have different tissue-specificities and functions (Kallwitz
et al., 2008). Whilst PPARγ is highly expressed in adipose tissue
and functions in adipocyte differentiation, PPARα functions as
a major regulator of lipid and glucose metabolism in the liver.
PPARβ/δ is ubiquitously expressed with a wide array of functions.
PPARα-agonists, the fibrates, are utilized to treat patients with ele-
vated plasma triglycerides (Sirtori and Franceschini, 1988) due to
the ability of PPARα to activate fatty acid oxidation and hepatic
lipid hydrolysis by regulating acyl CoA synthetase (Acs), carni-
tine palmitoyl transferase I (Cpt-I ), mitochondrial β-oxidation
enzymes, and hepatic lipases in addition to downregulating apoC-
III and decreasing hepatic triglyceride secretion (Kersten et al.,
1999; Pyper et al., 2010; Rakhshandehroo et al., 2010). Accord-
ingly, Pparα-deficient mice develop hepatic steatosis on a high-fat
diet (Abdelmegeed et al., 2011).
A case-control study of NAFLD patients highlighted a poten-
tially protective role for the Val227Ala variant of PPARα against
obesity compared to subjects with the wild-type receptor (Chen
et al., 2008a). The adipocyte differentiation regulator, PPARγ,
plays an important role in lipid homeostasis and insulin sen-
sitivity by enhancing fatty acid and insulin-dependent glucose
uptake in adipose tissue (Kallwitz et al., 2008). Moreover, novel
PPARγ agonists acting mainly on adipose Pparγ prevent forma-
tion of steatotic livers in mice by improving insulin resistance,
upregulating adiponectin, and downregulating leptin expression
and secretion (Zheng et al., 2011). Pparγ is expressed at low
levels in the liver but is upregulated in rodent fatty livers, con-
tributing to hepatic triglyceride accumulation with a protec-
tive effect to dyslipidemia and insulin resistance in other tis-
sues (Gavrilova et al., 2003). Upregulation of hepatic PPARγ is
also observed in obese NAFLD patients (Pettinelli and Videla,
2011).
PPARα affects the expression of several phase II enzymes such
as SULTs and UGT (Runge-Morris and Kocarek, 2009) as well as
of CYP3A4 and several other CYPs in humans (Rakhshandehroo
et al., 2009; Klein et al., 2012). Contrasting observations have been
made regarding the regulation of DMEs by PPARα in human ver-
sus mouse. While treatment of human primary hepatocytes with
the selective PPARα agonist WY14 643 resulted in the activation
of several drug metabolizing CYPs including CYP3A4, CYP2B6,
CYP2C8, and CYP1A2, none of the mouse gene orthologs were reg-
ulated (Rakhshandehroo et al., 2009). Downregulation of CYP3A4
in the presence of PPARα variants that result in decreased hepatic
PPARα protein levels was also found by genetic association analy-
sis and confirmed in a human atorvastatin volunteer study (Klein
et al., 2012). Moreover, activation of PPARα by agonists downreg-
ulates the expression of representatives genes of the Sult 1, 2, 3, and
5 families, specifically in female rats (Alnouti and Klaassen, 2008).
However, in human hepatocytes activation of PPARα resulted
in the upregulation of SULT2A1 via a functional PPRE, further
emphasizing species and gender differences in the functionality of
PPARα (Fang et al., 2005). Protein and mRNA levels of UGT1A1
increased upon PPARα activation in rat and human hepatocytes
(Jemnitz et al., 2000; Richert et al., 2003). Additionally, UGT1A3,
UGT1A4, and UGT1A6 are upregulated in human hepatocytes
and transgenic mice carrying the human UGT1 locus (Senekeo-
Effenberger et al., 2007). UGT2B4 is also enhanced after treatment
of human hepatocytes with PPARα agonists (Barbier et al., 2003).
Functional PPREs have been identified in the 5′-flanking regions of
UGT1A1, UGT1A3, UGT1A6, and UGT2B4 genes, thus providing
evidence that these genes are direct targets of PPAR (Barbier et al.,
2003; Senekeo-Effenberger et al., 2007). The widespread use of
drugs metabolized by SULTs and UGTs such as hormonal contra-
ceptives, acetaminophen,β2-adrenergic agonists, anti-depressants,
and non-steroidal anti-inflammatory drugs highlights the impli-
cations of altered PPARα activation on xenobiotic metabolism in
NAFLD patients.
Nuclear factor erythroid 2-related factor 2
Nuclear Factor Erythroid 2-related factor 2 (NRF2) is a tran-
scription factor that responds to oxidative/electrophilic stim-
uli by releasing from its repressor Kelch-like ECH associating
protein 1 (Keap1) in the cytosol, translocating to the nucleus,
binding to antioxidant response elements (AREs) upstream of
numerous phase II DME genes, and genes involved in redox
balance and oxidative stress response [e.g., heme oxygenase-1
(HO-1), NAD(P)H:quinone oxidoreductase-1 (NQO1)] and acti-
vating their transcription (Wu et al., 2012). NRF2 also regulates the
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glutathione synthesis enzyme, glutamate cysteine ligase catalytic
(GCLC). The expression of a canalicular biliary efflux transporter,
multidrug resistance protein 2 (MRP2/ABCC2) and sinusoidal
transporters, MRP3 and MRP4 is also regulated by NRF2 in mouse
liver and HepG2 cells in response to oxidative stress and xenobi-
otics, thus providing further evidence that phase II enzymes and
efflux transporters are regulated simultaneously (Vollrath et al.,
2006; Aleksunes et al., 2008). MRP2 is involved in the excretion
of reduced and oxidized glutathione and hence plays an impor-
tant role in detoxification and against oxidative stress. Nrf2-null
mice on MCD diet exhibit increased hepatic steatosis accom-
panied by inflammation and oxidative stress (Chowdhry et al.,
2010). Similarly, in rats on MCD diet, the NRF2-dependent genes
involved in the oxidative stress response were upregulated (Lick-
teig et al., 2007). Thus, NRF2 appears to have a crucial role in the
pathogenesis of NAFLD.
Thus, it is evident that as many of the lipids that accumulate
in obesity and steatosis, such as fatty acids, cholesterol, or bile
acids, are endogenous ligands of nuclear receptors, their deregula-
tion may not only exacerbate the deregulated metabolic processes
in NAFLD patients but also result in deregulated xenobiotic
metabolism.
PHASE I DMEs
CYP3A
The CYP3A sub-family of DMEs plays a predominant role in the
metabolism of statins. Statins, in monotherapy and in combina-
tion with other lipid-lowering drugs or antioxidants, are ben-
eficial in NAFLD patients by improving dyslipidemia (Athyros
et al., 2011; Fon Tacer and Rozman, 2011). The inter-individual
variability in the response to statins varies in NAFLD patients
based on their risk for cardiovascular diseases (Maroni et al.,
2011). Moreover, the CYP3A4 drug metabolizing activity is also
a factor influencing inter-individual variability and hence, is rel-
evant to NAFLD patients undergoing statin therapy. The level of
CYP3A protein correlates negatively with the severity of steatosis
in humans (Kolwankar et al., 2007). No changes were found in
the CYP3A4 mRNA level in human fatty liver samples at various
stages of NAFLD progression, however a trend of decreasing activ-
ity and protein levels was observed (Fisher et al., 2009b). In another
study, CYP3A4 activity significantly decreased in macrosteatotic
fatty livers and cultured human hepatocytes treated with fatty
acids (Donato et al., 2006, 2007). CYP3A4 also displays sexual
dimorphism with approximately twofold elevated expression in
premenopausal women (Wolbold et al., 2003), who display a more
favorable lipid profile compared to men (Williams, 2004). An
intron 6 polymorphism in CYP3A4 (rs35599367[T]) results in
decreased expression and activity of CYP3A4, with carriers of the
T allele requiring significantly lower doses of statins (Elens et al.,
2011; Wang et al., 2011). In accordance with the reduced CYP3A4
expression in NAFLD, studies to determine the association of the
rs35599367 CYP3A4 polymorphism in NAFLD cohorts will enable
the elucidation of statin dose selection in these patients. Moreover,
genetic variants in other factors implicated in NAFLD, endobiotic,
and xenobiotic metabolism such as PXR, PPARα, and POR have
also been associated with altered CYP3A4 expression and activity
(Zhang et al., 2008; Gomes et al., 2009; Klein et al., 2012). These
studies emphasize the high level of variability in responses to statin
treatments and may provide a basis for dose selection in NAFLD
patients based on CYP3A4 status (Table 2).
CYP2C9
CYP2C9 is the most abundant CYP of the CYP2C sub-family
in human liver microsomes, accounting for the metabolism of
a large number of clinically important drugs, especially some
with a narrow therapeutic index, such as warfarin. The expres-
sion of CYP2C9 is coordinated by nuclear receptors such as
CAR and PXR in association with nuclear factors and coacti-
vators such as hepatocyte nuclear factor-4 alpha (HNF-4α) and
PPARγ coactivator-1 alpha (PGC-1α), which is also involved
in energy homeostasis (Chen and Goldstein, 2009). CYP2C9
has been closely associated with adverse drug reactions. Its
mRNA and enzyme activity increase with NAFLD progression,
hypoxia, and at later stages of NASH in humans (Fisher et al.,
2009b). Previous observations linking CYP2C9 with arachi-
donic acid metabolism and vasocontraction in hypoxic condi-
tions (Pokreisz et al., 2006) may possibly provide an expla-
nation for elevated CYP2C9 in progressive NAFLD. Approxi-
mately 50 variants have been identified in the CYP2C9 gene to
date, with the CYP2C9∗2 and CYP2C9∗3 loss-of-function alle-
les as the most important. Heterozygotes and homozygotes for
these polymorphisms are common in Caucasians, with frequen-
cies of approximately 10–17 (CYP2C9∗2) and 7% (CYP2C9∗3).
Both polymorphic alleles were associated with increased response
to anti-diabetic sulfonylurea drugs and an increased glycemic
response in T2D patients (Zhou et al., 2010). As NAFLD patients
are treated with sulfonylureas, genotyping is clinically relevant.
Further studies are needed to identify the association of the
CYP2C9∗2 and CYP2C9∗3 variants with adverse drug reactions
such as hypoglycemia and weight gain resulting from sulfonylurea
treatment.
CYP2E1
CYP2E1, a fatty acid (Ω-1)-hydroxylase, catalyzes the oxidation
of many low molecular weight molecules, including ethanol and
acetone, a product of fatty acid oxidation. An important catalytic
feature of CYP2E1 is the generation of ROS such as superoxide
anion radical and hydrogen peroxide as a result of uncoupling
of oxygen consumption with NADPH oxidation and as a by-
product of lipid peroxidation (Robertson et al., 2001; Caro and
Cederbaum, 2004). It is also involved in the biotransformation
of xenobiotics such as acetaminophen, resulting in the generation
of toxic reactive metabolites (Aubert et al., 2011). NAFLD and
NASH patients and the MCD diet-fed rat model of NASH display
enhanced expression of CYP2E1, which is in contrast to all other
drug metabolizing CYPs, and elevated lipid peroxidation (Welt-
man et al., 1996, 1998; Videla et al., 2004) with increased localiza-
tion to hepatic areas with oxidative stress injuries. Obese females
with steatosis and NASH display elevated CYP2E1 protein levels
and a positive correlation between the c2 allele of Rsa1/Pst1 poly-
morphisms in CYP2E1 and liver injury (Varela et al., 2008). Mice
with silenced diacylglycerol acyltransferase 2 (Dgat2) on MCD diet
display elevated Cyp2e1 expression that correlates with increased
lipid peroxidation and oxidative damage, thus highlighting the
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role of CYP2E1 in the progression to NASH in response to
increased hepatic free fatty acids (Yamaguchi et al., 2007). An
upregulation in CYP2E1 has also been associated with leptine-
mia, reduced adiponectin levels, and insulin resistance in NAFLD
(Aubert et al., 2011). This phenomenon is reversed in patients
who have undergone bariatric surgery with resulting decreases in
weight and hepatic steatosis (Bell et al., 2010). With the robust
cellular protection mechanisms intact, increases in pro-oxidant
molecules and CYP2E1 are counteracted by increased levels of
glutathione (GSH). However, most NASH rodent models display
lower GSH, indicating defects in the oxidative stress response path-
ways in progressive NAFLD. Nitrosylation of antioxidant enzymes
superoxide dismutase (SOD) and catalase (CAT) is crucial in a
Cyp2e1-overexpressing mouse model of NAFLD (Kathirvel et al.,
2010) because increased levels of iNOS generates reactive nitro-
gen species (RNS), which nitrosylate antioxidant enzymes and
decrease their activity. Thus, CYP2E1 polymorphisms that asso-
ciate with the progression of NAFLD to NASH may possibly trigger
the combined detrimental effects of both ROS and RNS, which in
combination with toxic metabolites from xenobiotic biotransfor-
mation may result in further aggravated liver injury in NAFLD
patients.
Observations in a NAFLD pediatric population have indi-
cated a direct correlation between lipid peroxidation and disease
severity irrespective of CYP2E1 levels; however, the small sample
size of this study and the possibility of alternative mechanisms
of lipid peroxidation in early onset hepatic steatosis cannot be
excluded (Bell et al., 2011). Other groups have also previously
indicated decreased CYP2E1 mRNA and protein levels and no
changes in CYP2E1 activity at progressive stages of NAFLD (Fisher
et al., 2009b; Mitsuyoshi et al., 2009). Thus, no conclusive role of
CYP2E1 in NAFLD can be described. Interestingly, CYP4A genes
seem to compensate for microsomal lipid oxidation in the absence
of CYP2E1 as observed in Cyp2e1-null mice that display lipid
peroxidation and increased expression of Cyp4a10 and Cyp4a14
(Leclercq et al., 2000; Hardwick et al., 2009). This observation may
possibly explain the absence of changes in CYP2E1 activity in some
NAFLD populations.
CYP4A
CYP4A enzymes ω-hydroxylate fatty acids into dicarboxylic acids
that are preferentially oxidized by peroxisomes. Genes of the
CYP4A sub-family are induced by PPARα-agonists and in con-
ditions of fasting. The enhanced activity of CYP4A results in
increased production of ROS, thus contributing to steatohep-
atitis. In contrast, PPARα agonists prevent NASH by increasing
β-oxidation. Moreover, Pparα-null mice on MCD diet are more
prone to developing NASH in the absence of Cyp4a induction
(Ip et al., 2003). These observations suggest that the anti-steatotic
effects of PPARαmay be more potent than its activation of CYP4A
genes, hence overriding the ROS-generating effects of CYP4A. In
the absence of PPARα alternative oxidative stress mechanisms may
act as causal factors.
PHASE II DMEs
Phase II DMEs are conjugative, detoxification enzymes that trans-
form substrates into more excretable inactive forms or on the
other hand may also be involved in bioactivation. Glutathione-
S-transferases (GSTs) are present as different isoforms Alpha,
Mu, and Pi and conjugate electrophilic compounds with reduced
GSH (Hayes et al., 2005). While a GST A and P are upregulated
with disease progression in the livers of NAFLD patients, GST
M is significantly downregulated, thus highlighting the differen-
tial regulation of GST isoforms in NAFLD progression; however,
the overall GST activity was decreased in these samples (Hard-
wick et al., 2010). GSTM2, GSTM4, and GSTM5 mRNA lev-
els are expressed at lower levels in patients with steatosis and
NASH (Younossi et al., 2005). GSTs play a significant role in con-
trolling oxidative stress by conjugating harmful by-products of
oxidative stress with GSH (Hayes et al., 2005). Decreased GST
activity in progressive NAFLD samples was accompanied by a
reduced pool of GSH, highlighting the depleted ability to com-
bat oxidative stress, a causal factor for NASH (Hardwick et al.,
2010). The antioxidant, S-adenosyl-l-methionine (SAM) pro-
vides the cysteine moiety for the generation of GSH. Several
rodent studies have indicated a decrease in SAM on a high-fat
diet (Kwon do et al., 2009; Buechler and Weiss, 2011). Further-
more, GSTs have a lower expression in Caucasians compared
to African–Americans, who have a lower prevalence of NAFLD
(Stepanova et al., 2010). The GSTM1-null genotype, shown to
confer a higher risk of T2D, is also present at a higher frequency
in NAFLD subjects compared to control (Hori et al., 2007, 2009).
Thus, decreased activity of GSTs play a plausible role in NAFLD
progression as a result of increased damage by oxidative stress
(Table 3).
Sulfotransferases are involved in sulfation of several endoge-
nous steroids and xenobiotics. The sulfation of oxysterols by
SULT2B1b has anti-lipogenic properties by suppressing the LXR-
SREBP-1c interaction, resulting in significantly lower hepatic and
serum lipids as observed in low-density lipoprotein receptor
(Ldlr)-null mice on a high-fat diet (Bai et al., 2012). Moreover,
SULT1A2 gene expression is downregulated in NASH patients
compared to control obese individuals (Younossi et al., 2005).
SULT2A1 is upregulated by PPARα agonists in primary human
hepatocytes, but not in rat hepatocytes, due to the presence of a
PPRE in the 5′ region of the gene (Fang et al., 2005; Runge-Morris
and Kocarek, 2009). Thus, downregulation of PPARα observed
in NAFLD may have implications in the altered expression of
SULT2A1. However, only two SULT isoforms, SULT1C4 and
SULT4A1, whose regulation and function are largely unknown,
have increased mRNA and protein levels in human NASH sam-
ples compared to control and steatosis samples (Hardwick et al.,
2012a). A previous association of SULT4A1 in deregulated meta-
bolic homeostasis makes it a good candidate for further studies in
the context of NAFLD (Kiba et al., 2009).
UDP glucuronosyltransferases are involved in the glucuronida-
tion of 40–70% of all clinical drugs in humans (Wells et al., 2004).
UGT1A1, 1A3, 1A4, 1A6, and 2B4 are induced by PPARα-agonists
in primary human hepatocytes and PPREs have been identified
in these genes (Runge-Morris and Kocarek, 2009). Mice on high-
fat and high-sucrose diet, which develop severe hepatic steatosis,
display elevated expression of Ugt1a1 and Ugt1a6 mediated by
CAR and PXR (Osabe et al., 2008). A study in a pediatric NAFLD
population identified UGT1A1 as a risk factor for NAFLD. The
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UGT1A1∗6 allele in the coding region has a protective effect
against NAFLD in obese Taiwanese children (Lin et al., 2009).
UGT1A1 is involved in the glucuronidation of heme after break-
down to bilirubin. The ability of bilirubin to oxidize ROS may
provide protection against the progression of NAFLD. Addition-
ally, the high prevalence of unconjugated hyperbilirubinemia was
detected in NAFLD patients (25.4%) that were diagnosed with
less severe forms of NAFLD (Kumar et al., 2012). However, the
absence of changes in glucuronidation activity in human steatosis
and NASH liver samples warrants the need for further studies to
investigate the role of UGTs in NAFLD (Hardwick et al., 2012a).
TRANSPORTERS
Solute carrier transporters are uptake transporters that transport
molecules from the blood into the hepatocyte. Studies in rat and
human samples have indicated a coordinated downregulation of
uptake transporter genes in NASH, such as the sodium/bile acid
transporter (NTCP), organic anion transporting polypeptide 1a1
(OATP1a1), 1a4, 1b2, 2b1, OAT2, and OAT3. The expression of
these transporters is significantly altered in the transition from
steatosis to NASH rather than between control and steatotic sam-
ples (Fisher et al., 2009a; Lake et al., 2011). These changes appear
to be hepatoprotective to prevent the accumulation of toxic inter-
mediates and xenobiotics in the diseased liver. However, they have
major implications in therapeutic regimens in NAFLD patients in
terms of dose selection and side effects of drugs due to excessive
accumulation (Table 3).
Transporters on the hepatocyte canalicular membranes are
involved in the secretion of several endobiotics and xenobiotics via
the bile. ABC-transporters are the most extensively studied and are
altered in steatotic and NASH livers (Buechler and Weiss, 2011).
Of particular interest is Mrp2/Abcc2, which is decreased in several
rodent models of obesity, NAFLD and NASH and is normalized
upon rosiglitazone treatment (Geier et al.,2005; Fisher et al.,2009a;
Martin et al., 2010). Furthermore, the rs17222723 and rs8187710
variants in ABCC2 significantly associate with NAFLD and clini-
cal and histological parameters (Sookoian et al., 2009). Decreased
levels of ABCC2 protein may result in hampered secretion of bile,
leading to the accumulation of cholesterol and drug-related tox-
icities. As mentioned previously, this may result from impaired
NRF2 function.
CONCLUSION AND FUTURE DIRECTIONS
The high prevalence of NAFLD is concerning in terms of gen-
eral population health and also drug treatment regimens. A recent
study in mice has identified that the feed-forward cycle of con-
tinuous exposure to high-fat diet over two generations leads to
a significantly higher degree of obesity, NAFLD, insulin and lep-
tin resistance, and epigenetic modifications resulting in increased
lipogenesis and ER stress in future generations (Li et al., 2011). If
these observations are also true for humans, the rising epidemics
of obesity and NAFLD will expand exponentially in the absence of
serious efforts to tackle these conditions.
With the widespread prevalence of NAFLD, the proportion of
patients with steatotic livers undergoing drug therapies for vari-
ous disorders has also increased. The variability of drug treatment
responses in these patients highlights the need for personalized
therapeutic regimens. As detailed in this review, several compo-
nents of the drug metabolism pathway are significantly affected
in the presence of NAFLD. Similarly, genetic variations in DMEs
and nuclear receptors associate with NAFLD with either positive
or negative prognosis. Hence, inter-dependent interactions and
common confounding factors exist between the pathogenesis of
NAFLD and altered drug metabolism. As a majority of the DMEs
are also involved in the metabolism of steroids and other lipids,
polymorphisms in DMEs resulting in non-functional proteins may
further aggravate the prognosis of NAFLD. The utility of identified
genetic associations to determine NAFLD disease susceptibility,
improve drug sensitivity or prevent adverse drug reactions holds
great potential. Further efforts to characterize DMEs and iden-
tify risk factors for adverse drug reactions or treatment efficacies
in NAFLD populations may lead to the utilization of innova-
tive interdisciplinary strategies to provide a better insight into the
pharmacokinetic profile of drugs and their efficacy. Although the
implementation of these findings in the clinic is still a long-term
goal with hurdles to pass, novel technologies and increasing inter-
est in this field continues to increase our understanding of NAFLD
and its interactions with drug metabolism.
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